Meeting
2018 Genitourinary Cancers Symposium
Niclosamide in combination with abiraterone and prednisone in men with castration-resistant prostate cancer (CRPC): initial results from a phase Ib/II trial.
Authors
Chong-xian Pan
University of California Davis Comprehensive Cancer Center, Sacramento, CA
Chong-xian Pan , Primo Lara Jr., Christopher P. Evans , Mamta Parikh , Marc Dall'era , Chengfei Liu , Daniel Robles , Allen Gao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02807805
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 192)
DOI
10.1200/JCO.2018.36.6_suppl.192
Abstract #
192
Poster Bd #
J12
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
BMX inhibition and HSD3B1-driven resistance in prostate cancer in the Maverick trial.
First Author: Nima Sharifi
Poster
2024 ASCO Genitourinary Cancers Symposium
Final study analysis of PRINT: Prostate cancer intensive, non–cross-reactive therapy for CRPC.
First Author: Bobby Chi-Hung Liaw
Poster
2020 Genitourinary Cancers Symposium
A phase Ib/II open-label study of tazemetostat (TAZ) plus enzalutamide (E) or abiraterone/prednisone (A/P) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Wassim Abida
Poster
2020 Genitourinary Cancers Symposium
A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Michael C. Burns